Details
Stereochemistry | ABSOLUTE |
Molecular Formula | C25H31N7O3 |
Molecular Weight | 477.5587 |
Optical Activity | UNSPECIFIED |
Defined Stereocenters | 1 / 1 |
E/Z Centers | 0 |
Charge | 0 |
SHOW SMILES / InChI
SMILES
CN1C(CNC2=CC=C(C=C2)C(N)=N)=NC3=C1C=CC(=C3)[C@@](C)(NCC(O)=O)C(=O)N4CCCC4
InChI
InChIKey=MAOALPSHCIBFJZ-RUZDIDTESA-N
InChI=1S/C25H31N7O3/c1-25(29-15-22(33)34,24(35)32-11-3-4-12-32)17-7-10-20-19(13-17)30-21(31(20)2)14-28-18-8-5-16(6-9-18)23(26)27/h5-10,13,28-29H,3-4,11-12,14-15H2,1-2H3,(H3,26,27)(H,33,34)/t25-/m1/s1
Molecular Formula | C25H31N7O3 |
Molecular Weight | 477.5587 |
Charge | 0 |
Count |
|
Stereochemistry | ABSOLUTE |
Additional Stereochemistry | No |
Defined Stereocenters | 1 / 1 |
E/Z Centers | 0 |
Optical Activity | UNSPECIFIED |
Tanogitran (also called as BIBT986) is a dual inhibitor of thrombin/factor Xa. Tanogitran participated in a clinical trial in endotoxin-induced coagulation, where was shown that tanogitran was a potent anticoagulant. In addition, the drug was studied in phase II clinical trial for the treatment of septic shock; however, information about the further development of this drug is not available.
Approval Year
Sample Use Guides
In Vivo Use Guide
Sources: https://www.ncbi.nlm.nih.gov/pubmed/17410124
Participants received one of three doses of BIBT986 or placebo intravenously together with a bolus infusion of 2 ng/kg lipopolysaccharide (LPS).
Route of Administration:
Intravenous
Substance Class |
Chemical
Created
by
admin
on
Edited
Sat Dec 16 16:12:05 GMT 2023
by
admin
on
Sat Dec 16 16:12:05 GMT 2023
|
Record UNII |
X5QRR6Z56Q
|
Record Status |
Validated (UNII)
|
Record Version |
|
-
Download
Name | Type | Language | ||
---|---|---|---|---|
|
Official Name | English | ||
|
Code | English | ||
|
Systematic Name | English | ||
|
Common Name | English | ||
|
Code | English |
Classification Tree | Code System | Code | ||
---|---|---|---|---|
|
NCI_THESAURUS |
C263
Created by
admin on Sat Dec 16 16:12:05 GMT 2023 , Edited by admin on Sat Dec 16 16:12:05 GMT 2023
|
Code System | Code | Type | Description | ||
---|---|---|---|---|---|
|
C90705
Created by
admin on Sat Dec 16 16:12:05 GMT 2023 , Edited by admin on Sat Dec 16 16:12:05 GMT 2023
|
PRIMARY | |||
|
9826322
Created by
admin on Sat Dec 16 16:12:05 GMT 2023 , Edited by admin on Sat Dec 16 16:12:05 GMT 2023
|
PRIMARY | |||
|
300000034385
Created by
admin on Sat Dec 16 16:12:05 GMT 2023 , Edited by admin on Sat Dec 16 16:12:05 GMT 2023
|
PRIMARY | |||
|
637328-69-9
Created by
admin on Sat Dec 16 16:12:05 GMT 2023 , Edited by admin on Sat Dec 16 16:12:05 GMT 2023
|
PRIMARY | |||
|
8408
Created by
admin on Sat Dec 16 16:12:05 GMT 2023 , Edited by admin on Sat Dec 16 16:12:05 GMT 2023
|
PRIMARY | |||
|
CHEMBL1270156
Created by
admin on Sat Dec 16 16:12:05 GMT 2023 , Edited by admin on Sat Dec 16 16:12:05 GMT 2023
|
PRIMARY | |||
|
X5QRR6Z56Q
Created by
admin on Sat Dec 16 16:12:05 GMT 2023 , Edited by admin on Sat Dec 16 16:12:05 GMT 2023
|
PRIMARY |
Related Record | Type | Details | ||
---|---|---|---|---|
|
TARGET -> INHIBITOR |
IC50
|
||
|
TARGET -> INHIBITOR |
IC50
|
Related Record | Type | Details | ||
---|---|---|---|---|
|
ACTIVE MOIETY |